Medicinova, Inc. (MNOV) Dividend History

Company News

• MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025

  MediciNova, Inc. announced the enrollment of the first patient in an NIH-funded Expanded Access Program (EAP) trial to evaluate their drug MN-166 for the treatment of amyotrophic lateral sclerosis (ALS).

  GlobeNewswire Inc.
• MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

  MediciNova, a biopharmaceutical company, announced that it was notified by Sanofi that the Sanofi/Novartis litigation was settled. As a result, MediciNova is entitled to receive a certain amount of monetary damages through this settlement, which it plans to use to support its ongoing clinical development programs.

  GlobeNewswire Inc.
• MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

  MediciNova will provide investigational drug MN-166 (ibudilast) and support for an NIH-funded expanded access clinical trial to evaluate the drug's efficacy in treating Amyotrophic Lateral Sclerosis (ALS).

  GlobeNewswire Inc.
• MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

  MediciNova announced that an abstract regarding a clinical trial of MN-166 (ibudilast) in the treatment of Amyotrophic Lateral Sclerosis (ALS) has been selected for a poster presentation at the 35th International Symposium on ALS / MND.

  GlobeNewswire Inc.
• MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

  MediciNova announced that an abstract regarding its MN-166 (ibudilast) drug in the COMBAT-ALS Phase 2b/3 clinical trial has been accepted for presentation at the 2024 Annual NEALS Meeting.

  GlobeNewswire Inc.